Chemclin Diagnostics(SH:688468)2025-04-28 13:35Financial Performance - The company's operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27.01% compared to ¥111,390,688.04 in the same period last year[4] - Net profit attributable to shareholders was ¥14,542,813.84, down 62.12% from ¥38,392,507.40 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥11,131,421.96, reflecting a decline of 68.00% compared to ¥34,787,360.92 in the previous year[4] - Basic and diluted earnings per share were both ¥0.04, a decrease of 60.00% from ¥0.10 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥81,300,127.46, a decrease of 27% compared to ¥111,390,688.04 in Q1 2024[18] - Net profit for Q1 2025 was ¥14,542,813.84, a decline of 62% from ¥38,392,507.40 in Q1 2024[19] - Earnings per share for Q1 2025 was ¥0.04, compared to ¥0.10 in Q1 2024, indicating a 60% decrease[19] - Cash received from sales of goods and services in Q1 2025 was ¥90,331,179.04, down 30% from ¥129,981,796.53 in Q1 2024[21] Cash Flow and Assets - The net cash flow from operating activities decreased by 59.74%, amounting to ¥15,204,001.57, down from ¥37,767,684.23[4] - Total assets at the end of the reporting period were ¥1,815,591,513.49, a decrease of 0.90% from ¥1,832,158,296.89 at the end of the previous year[5] - As of March 31, 2025, the company's total current assets amounted to RMB 1,049,855,808.49, a decrease from RMB 1,067,681,904.23 as of December 31, 2024, reflecting a decline of approximately 1.14%[13] - The company's cash and cash equivalents stood at RMB 401,225,526.99, slightly increasing from RMB 400,252,111.81 in the previous period[13] - Total cash inflow from investment activities was $464,799,073.09, down from $503,609,819.16, resulting in a net cash outflow of $51,537,903.44 compared to a net inflow of $60,935,030.35 previously[22] - The ending balance of cash and cash equivalents was $106,768,979.00, significantly lower than $277,035,240.30 at the end of the previous period[23] Liabilities and Equity - Total liabilities decreased to ¥384,741,562.28 from ¥415,851,159.52, representing a reduction of approximately 7.5%[15] - Non-current liabilities totaled ¥237,393,000.93, a slight increase from ¥232,502,428.90[15] - The company reported a decrease in accounts payable from ¥66,627,322.85 to ¥36,201,224.37, a reduction of about 46%[15] - Shareholders' equity attributable to shareholders was ¥1,430,849,951.21, an increase of 1.03% from ¥1,416,307,137.37 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥17,156,877.91, a decrease of 14.62% from ¥20,095,592.77 year-on-year[4] - The proportion of R&D expenses to operating revenue increased to 21.10%, up 3.06 percentage points from 18.04%[5] - The company is focusing on R&D investments to enhance technology and product innovation, aiming to meet unmet clinical needs and drive import substitution[12] - The company has established a dual-driven strategy focusing on import substitution and clinical interactive innovation to enhance its product pipeline[12] - The company has a robust product pipeline prepared in advance to navigate industry challenges and aims to create a "new quality productivity" for long-term growth[12] Non-Recurring Gains and Other Income - The company reported non-recurring gains totaling ¥3,411,391.88, primarily due to various non-operating income sources[7] Shareholder Information - The top ten shareholders include Ningbo Baoshui District Yingweili Enterprise Management Partnership with 108,000,008 shares, representing a significant stake in the company[11]